Pages that link to "Q26992979"
Jump to navigation
Jump to search
The following pages link to Basal insulin combined incretin mimetic therapy with glucagon-like protein 1 receptor agonists as an upcoming option in the treatment of type 2 diabetes: a practical guide to decision making (Q26992979):
Displaying 6 items.
- The Role of Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: Understanding How Data Can Inform Clinical Practice in Korea (Q26852590) (← links)
- Pleiotropic effects of insulin and GLP-1 receptor agonists: Potential benefits of the association (Q28076059) (← links)
- Causes and consequences of obesity: epigenetics or hypokinesis? (Q36079417) (← links)
- Current therapeutic approaches in the management of hyperglycemia in chronic renal disease. (Q39160771) (← links)
- Why is a combination of basal insulin with a GLP-1 receptor agonist useful in many patients with type 2 diabetes? (Q51262448) (← links)
- Intensification of Basal Insulin Therapy with Lixisenatide in Patients with Type 2 Diabetes in a Real-World Setting: The BASAL-LIXI Study (Q59137107) (← links)